An experience with plasma exhcange treatment of acute lymphoblastic leukemia in a case with fulminant hepatitis related to l-asparaginase
dc.contributor.author | Bilgir O. | |
dc.contributor.author | Calan M. | |
dc.contributor.author | Bilgir F. | |
dc.contributor.author | Cagliyan G. | |
dc.contributor.author | Arslan O. | |
dc.date.accessioned | 2024-07-22T08:18:17Z | |
dc.date.available | 2024-07-22T08:18:17Z | |
dc.date.issued | 2013 | |
dc.description.abstract | Acute lymphoblastic leukemia (ALL) is a malignant disorder resulting from the clonal proliferation of lymphoid precursors with arrested maturation. l-asparaginase is commonly used in combination chemotherapy of both pediatric and adult acute lymphoblastic leukemias. The most commonly encountered side effects of l-asparaginase are hypersensitivity reactions like pyrexia, urticaria, skin rash, and respiratory distress. There are also other side effects like anaphylaxis, coagulopathy, pancreatitis, thrombosis, and hepatic toxicity. Plasmapheresis can sometimes be appropriate to manage an overdose of drugs that circulate in the plasma compartment. We have reported plasmapheresis treatment of fulminant hepatitis in a patient with ALL after l-asparaginase treatment. © 2013 Elsevier Ltd. | |
dc.identifier.DOI-ID | 10.1016/j.transci.2013.06.010 | |
dc.identifier.issn | 18781683 | |
dc.identifier.uri | http://akademikarsiv.cbu.edu.tr:4000/handle/123456789/17261 | |
dc.language.iso | English | |
dc.subject | Antineoplastic Agents | |
dc.subject | Asparaginase | |
dc.subject | Drug-Induced Liver Injury | |
dc.subject | Female | |
dc.subject | Humans | |
dc.subject | Liver Failure, Acute | |
dc.subject | Middle Aged | |
dc.subject | Plasma Exchange | |
dc.subject | Precursor Cell Lymphoblastic Leukemia-Lymphoma | |
dc.subject | Fulminant hepatic failure | |
dc.subject | l-Asparaginase | |
dc.subject | Plasmapheresis | |
dc.subject | asparaginase | |
dc.subject | daunorubicin | |
dc.subject | prednisone | |
dc.subject | vincristine | |
dc.subject | antineoplastic agent | |
dc.subject | asparaginase | |
dc.subject | acute lymphoblastic leukemia | |
dc.subject | adult | |
dc.subject | article | |
dc.subject | bilirubin blood level | |
dc.subject | bone marrow biopsy | |
dc.subject | cancer combination chemotherapy | |
dc.subject | case report | |
dc.subject | drug dose reduction | |
dc.subject | fatigue | |
dc.subject | female | |
dc.subject | fever | |
dc.subject | hepatitis | |
dc.subject | human | |
dc.subject | plasmapheresis | |
dc.subject | side effect | |
dc.subject | treatment response | |
dc.subject | acute liver failure | |
dc.subject | acute lymphoblastic leukemia | |
dc.subject | chemically induced disorder | |
dc.subject | fulminant hepatic failure | |
dc.subject | l-Asparaginase | |
dc.subject | middle aged | |
dc.subject | toxic hepatitis | |
dc.title | An experience with plasma exhcange treatment of acute lymphoblastic leukemia in a case with fulminant hepatitis related to l-asparaginase | |
dc.type | Article |